Spectrum Pharma (SPPI): Cutting PT After apaziquone Rejection - RBC

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) but reduced his price target to $10 from $11 after apaziquone was voted down.

The FDA’s cancer drug advisory committee voted against apaziquone approval. The panel found apaziquone promising due to the unmet need, however, statistical analyses were the hurdle and something the FDA had repeatedly emphasized. Since the unmet need is there, the end market is large and the space remains unchanged, the analyst believes the opportunity is worth pursuing as a third Phase 3 started in 2015.

For an analyst ratings summary and ratings history on Spectrum Pharmaceuticals click here. For more ratings news on Spectrum Pharmaceuticals click here.

Shares of Spectrum Pharmaceuticals closed at $5.04 yesterday.

You May Also Be Interested In

• Williams-Sonoma (WSM) PT Raised to $260 at RBC Capital
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker